SARS-CoV-2 Nucleocapsid (N) Protein #VPN1

Aliases: Severe acute respiratory syndrome coronavirus 2 nucleocapsid; 2019 novel coronavirus nucleoprotein, SARS-CoV-2 NP, SARS-CoV-2 N protein

UniProt Accession No.: P0DTC9

Host Species: SARS-CoV-2 nucleocapsid (N) protein is a recombinant protein produced in insect cells.

Amino Acid Sequence: MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAGLPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKHWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQAHHHHHH

Purity: > 95% as established by reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis

Tag: Six histidine (His) residues at the C-terminus of the protein

Molecular Weight: 49 kDa

Validated Applications: ELISA

Storage Buffer: 0.02 M Tris buffer, pH 8.0

Storage Condition: < -20°C, stable for 1 year after receipt. Avoid repeated freeze-thaw cycles.

The single-stranded, plus-sense severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2) genome encodes nonstructural replicase polyproteins as well as structural proteins such as spike (S), nucleocapsid (N), membrane (M) and envelop (E) proteins (Zhou et al., 2020). The N protein is abundantly expressed and highly immunogenic during SARS-CoV-2 infection (Cong et al., 2020). The middle or C-terminal region of the N protein has been shown to elicit antibody production during the immune response (Dutta et al., 2020). Although the surface electrostatic potential characteristics of SARS-CoV-2 N are different from other coronavirus N proteins (Kang et al., 2020), the sequences are conserved among these proteins (Dutta et al., 2020). Besides S protein, N protein is also considered a leading target antigen for vaccine development (Chen et al., 2020; Dutta et al., 2020).

 

Chen, W.H., Strych, U., Hotez, P.J., and Bottazzi, M.E. (2020). The SARS-CoV-2 Vaccine Pipeline: An Overview. Curr Trop Med Rep, 1-4.

Cong, Y., Ulasli, M., Schepers, H., Mauthe, M., V'Kovski, P., Kriegenburg, F., Thiel, V., de Haan, C.A.M., and Reggiori, F. (2020). Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle. J Virol 94.

Dutta, N.K., Mazumdar, K., and Gordy, J.T. (2020). The Nucleocapsid Protein of SARS-CoV-2: A Target for Vaccine Development. J Virol 94.

Kang, S., Yang, M., Hong, Z., Zhang, L., Huang, Z., Chen, X., He, S., Zhou, Z., Zhou, Z., Chen, Q., et al. (2020). Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B 10, 1228-1238.

Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273.

• Recombinant protein in insect cells

• Verified with monoclonal antibodies using contrived human nasopharyngeal swab specimens

• Can be used as an antigen to detect IgM and IgG antibodies in COVID-19 patients

SARS-CoV-2 Nucleocapsid (N) Protein #VPN1